Search Results

You are looking at 171 - 180 of 817 items for :

  • "screening" x
Clear All
Full access

Lydia F.J. van Overveld, Robert P. Takes, Jozé C.C. Braspenning, Robert J. Baatenburg de Jong, Jan P. de Boer, John J.A. Brouns, Rolf J. Bun, Eric A. Dik, Boukje A.C. van Dijk, Robert J.J. van Es, Frank J.P. Hoebers, Barry Kolenaar, Arvid Kropveld, Ton P.M. Langeveld, Hendrik P. Verschuur, Jan G.A.M. de Visscher, Stijn van Weert, Max J.H. Witjes, Ludi E. Smeele, Matthias A.W. Merkx and Rosella P.M.G. Hermens

aspects regarding coordination and communication), 18 process indicators from the perspective of AHPs (malnutrition screening and involvement of speech therapist), and 3 structure indicators from the perspective of AHPs (number of available case managers

Full access

David D. Buethe and Julio Pow-Sang

free/total prostate specific antigen levels and needle biopsy findings . J Urol 1998 ; 160 : 2407 – 2411 . 5 Draisma G Boer R Otto SJ . Lead times and overdetection due to prostate-specific antigen screening: estimates from the European

Full access

John H. Ward

NCCN has developed NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of cancer, management of complications, and screening. The NCCN Guidelines, regularly updated, are a fusion of scientific data and expert opinion

Full access

Joleen M. Hubbard and Axel Grothey

women from 1998 to 2009, largely attributed to be an effect of CRC screening. 3 Etiology The exact cause for this alarming trend in young adults is unclear, but has largely been attributed to dietary factors and the rising rate of obesity among

Full access

Kshama Jaiswal, Madelyne Hull, Anna L. Furniss, Reina Doyle, Natalia Gayou and Elizabeth Bayliss

urgent care visit with specific breast complaints, such as mass, discharge, pain) or asymptomatic (ie, patient had an abnormal screening mammogram). If screening mammography was the method of presentation, the first image was defined as the date of

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas and Catherine H. Van Poznak

quality of life, and increased risk of death. 1 Much of the morbidity and mortality associated with bone loss can be prevented with appropriate screening, lifestyle interventions, and therapy. Both cancer itself and cancer therapies can have profound

Full access

Heather Bowers, Kerri Susko, Aniket Saha and Elizabeth Cull

center were enrolled on a clinical trial. Conclusion: In our quality improvement initiative in year 2, we increased referrals to the AYA clinic, referrals to specialist services, and clinical trial enrollment. Screening AYA patients on a weekly basis is

Full access

Kimberly Byrwa-Neff, Wendi Waugh and Rhondalyn Bomkamp

improvement when changes were implemented relative to scheduling; days from screening to diagnostic mammogram in 2017 was 21.8 days versus 6.5 days in 2018. Patients with BI-RADS 4 or 5 experienced improved timelines from diagnostic mammogram to biopsy, 4

Full access

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford and Melinda L. Telli

, representing one of the shortest reported latent periods to secondary malignancy in a patient with LFS. Because of the expense and psychosocial stress associated with genetic testing, screening all patients with early-onset breast cancer for LFS generally has

Full access

William T. McGivney

Recent decisions about the optimal frequency and population age for screening mammography and the appropriate uses of bevacizumab and sipuleucel-t have raised questions, if not concerns, about both the decision-making processes and the level of